Allergan for sustained-release eye treatments.

Regeneron for long-lasting, implantable eye therapies.

• ReSure Sealant: An ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery.
• DEXTENZA: A dexamethasone ophthalmic insert used to treat post-surgical ocular inflammation and pain after ophthalmic surgery, and allergic conjunctivitis.
• OTX-TKI: An axitinib intravitreal implant in Phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases.
• OTX-TIC: A travoprost intracameral implant in Phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
• OTX-CSI: A cyclosporine intracanalicular insert that has completed Phase 2 clinical trials for the treatment of dry eye disease.
• OTX-DED: A dexamethasone intracanalicular insert in Phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.

Ocular Therapeutix (OCUL) sells its products and technologies primarily to other companies and healthcare institutions.

Its major customers include:

• Hospitals and Surgical Centers: These institutions purchase Ocular Therapeutix's marketed products, ReSure Sealant and DEXTENZA, for use in ophthalmic surgeries.
• Ophthalmology Clinics/Practices: These medical practices purchase DEXTENZA for conditions like allergic conjunctivitis and would be the prescribers for Ocular Therapeutix's future ophthalmic products.
• Regeneron Pharmaceuticals, Inc. (symbol: REGN): A strategic collaboration partner that licenses Ocular Therapeutix's sustained-release hydrogel technology for combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases.
• AffaMed Therapeutics Limited: A strategic collaboration partner for the development and commercialization of DEXTENZA and OTX-TIC. AffaMed Therapeutics is a private company and does not have a public symbol.

• Regeneron Pharmaceuticals, Inc. (REGN)
• Mosaic Biosciences

Pravin U. Dugel, MD - President and Chief Executive Officer

Dr. Pravin U. Dugel assumed the roles of President and Chief Executive Officer of Ocular Therapeutix on April 15, 2024, having previously served as Executive Chairman. His prior leadership experience includes serving as President of IVERIC Bio, Inc., Managing Partner at Retinal Consultants of Arizona and the Retinal Research Institute, Clinical Professor at USC Eye Institute, Keck School of Medicine, and a Founding Member of Spectra Eye Institute. Dr. Dugel founded an aviation company that enabled him to travel to Native American reservations to treat patients suffering from preventable blindness. He has consulted for over 50 companies and has held positions on the Boards of Directors for IVERIC Bio and Aerpio Therapeutics. Dr. Dugel is recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials.

Donald Notman - Chief Financial Officer and Chief Operating Officer

Donald Notman has served as Chief Financial Officer of Ocular Therapeutix since September 2017 and was appointed Chief Operating Officer in September 2024. As of January 20, 2026, Mr. Notman is on a temporary medical leave of absence. Before joining Ocular Therapeutix, he was Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc. Mr. Notman also held the position of Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was instrumental in developing the firm's healthcare investment banking capabilities. His career also includes senior-level investment banking roles with Deutsche Banc Alex. Brown and Alex. Brown & Sons.

Jeffrey S. Heier, MD - Chief Scientific Officer

Dr. Jeffrey S. Heier joined Ocular Therapeutix's management team as Chief Scientific Officer in February 2024. He is the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB). From 2016 to 2020, Dr. Heier served as co-president & medical director of OCB. He is the Immediate Past President of the Retina Society, a former member of the Executive Committee of the American Society of Retina Specialists, Past President of the New England Ophthalmological Society, and a member of the Macula Society.

Rabia Gurses Ozden, MD - Chief Medical Officer

Dr. Rabia Gurses Ozden continues in her role as Chief Medical Officer, a position she held as of February 2024. She was appointed as Senior Vice President, Clinical Development, in January 2021.

Peter Jarrett, PhD - Chief Technical Officer

Dr. Peter Jarrett assumed the new role of Chief Technical Officer in February 2024. He brings over 40 years of research and development experience, spanning from discovery to commercialization, and joined Ocular Therapeutix in 2007. Previously, he served as Vice President of R&D at Focal, and subsequently as VP of Biomaterials R&D at Genzyme following Genzyme's acquisition of Focal. Dr. Jarrett began his career in Corporate R&D at American Cyanamid and later moved to its Davis and Geck division. His work has focused on developing bioresorbable polymers for medical devices and drug delivery systems, leading to numerous patents and publications.

The key risks for Ocular Therapeutix (OCUL) primarily stem from the inherent challenges of biopharmaceutical development and commercialization in highly competitive ophthalmic markets.

1. Clinical Development, Regulatory Approval, and Market Adoption Risk for AXPAXLI (OTX-TKI)

Ocular Therapeutix faces significant risk related to the successful clinical development, regulatory approval, and subsequent market adoption of AXPAXLI (formerly OTX-TKI), its lead candidate for wet age-related macular degeneration (AMD). Despite recent "positive" Phase 3 SOL-1 trial data, the company's stock experienced a substantial drop, indicating that market expectations for AXPAXLI's durability advantage over existing therapies were not fully met. The company is reportedly pursuing an accelerated regulatory strategy, aiming for approval based on one-year data from a single pivotal trial (SOL-1), which concentrates significant regulatory, clinical, and valuation risk. The FDA's typical guidance for new drug applications in chronic diseases like wet AMD often recommends at least two adequate and well-controlled trials. Furthermore, there are concerns that the observed durability advantage of AXPAXLI in trial settings might diminish in real-world clinical practice, where more stringent retreatment criteria are often applied by retina specialists. Future clinical trial readouts for other programs, such as SOL-R (expected Q1 2027) and HELIOS-3, are anticipated to introduce similar market volatility.

2. Intense Market Competition

The ophthalmic pharmaceutical market is highly competitive, particularly in key therapeutic areas targeted by Ocular Therapeutix's products. The wet AMD market, for instance, is dominated by established blockbuster drugs such as Regeneron's Eylea and Roche's Vabysmo, with Regeneron also having introduced a longer-acting version, Eylea HD. For AXPAXLI to achieve commercial success, it must effectively differentiate itself in this fierce landscape, especially if its durability advantage is not perceived as transformative by the market. Similarly, DEXTENZA, one of the company's marketed products, faces competition from various corticosteroid eye drops. This intense competition necessitates continuous innovation and effective marketing to gain and maintain market share for both current and pipeline products.

3. Commercialization Challenges and Financial Performance

Ocular Therapeutix has demonstrated challenges in effectively commercializing its marketed products, which could impact the future success of its pipeline. The company has reported declining revenue from DEXTENZA, attributed primarily to reimbursement hurdles, despite achieving record annual unit volume. These "commercial execution headwinds" could foreshadow difficulties in penetrating the market with AXPAXLI, even if approved. Financially, the company has experienced widening trailing twelve-month losses and ongoing, sizeable financial losses. While Ocular Therapeutix maintains a robust cash position providing a runway into 2028, sustained losses without significant revenue growth from new product launches pose a long-term financial risk.

ReSure Sealant (Corneal Incisions Following Cataract Surgery)

The global ocular adhesives and sealants market, which includes products like ReSure Sealant used in ophthalmic surgeries, was valued at approximately USD 136.7 million in 2021 and is expected to grow. Annually, around 3 million cataract surgeries are performed in the United States, with over 20 million procedures worldwide. Global cataract surgeries are projected to increase to 50 million by 2050, indicating a substantial addressable market for wound sealants in this area.

DEXTENZA (Post-Surgical Ocular Inflammation and Pain; Allergic Conjunctivitis)

• Post-Surgical Ocular Inflammation and Pain: The global post-operative cataract surgery inflammation treatment market is estimated at USD 5.2 billion in 2025 and is projected to reach USD 10.0 billion by 2035. The global acute ocular pain market, where post-operative eye pain represents a significant application, is projected to grow from USD 2.1 billion in 2024 to USD 3.1 billion by 2030. In 2024, post-operative eye pain constituted approximately USD 0.88 billion of this market.
• Allergic Conjunctivitis: The global allergic conjunctivitis market was valued at USD 3.85 billion in 2023 and is expected to grow to USD 7.61 billion by 2034. Another estimate places the global market at USD 4.8 billion in 2023, projected to reach USD 7.2 billion by 2033. In the United States, an estimated 10 million people annually seek medical attention for allergic conjunctivitis. The U.S. held a significant share of the overall 7MM (United States, EU4, UK, and Japan) allergic conjunctivitis market in 2024.

OTX-TKI (Wet Age-Related Macular Degeneration and Other Retinal Diseases)

• Wet Age-Related Macular Degeneration (wAMD): The global wet age-related macular degeneration market was valued at USD 9.4 billion in 2024 and USD 9,528.8 million across the top 7 markets (US, EU4, UK, and Japan) in 2024. This market is projected to reach USD 18,317.5 million by 2035. The U.S. market alone for wet AMD was approximately USD 2,599 million in 2023.
• Other Retinal Diseases (Overall Retinal Disorder Treatment): The global retinal disorder treatment market was valued at approximately USD 18.3 billion in 2024 and is estimated to grow to USD 34.8 billion by 2034. The U.S. retinal disorder treatment industry was valued at USD 7.1 billion in 2024 and is projected to reach USD 13.1 billion by 2034.

OTX-TIC (Open-Angle Glaucoma or Ocular Hypertension)

• Open-Angle Glaucoma: The global open-angle glaucoma market was valued at USD 5.4 billion in 2024 and USD 7.88 billion in 2023, with projections to reach USD 13.51 billion by 2030. The market across the top 7 markets (US, EU4, UK, and Japan) for open-angle glaucoma reached USD 6.0 billion in 2024 and is expected to reach USD 8.7 billion by 2035.
• Ocular Hypertension: The global ocular hypertension market is estimated to be valued at USD 4.07 billion in 2025, with an expected increase to USD 5.46 billion by 2032. Another report projects the global market to grow from USD 5.1 billion in 2024 to USD 7.2 billion by 2030. The U.S. ocular hypertension market is projected to be USD 1.78 billion in 2024, expanding to USD 2.34 billion by 2030. The United States represents the largest patient pool and market for ocular hypertension treatment.

OTX-CSI and OTX-DED (Dry Eye Disease)

The global dry eye disease market was valued at USD 6.43 billion in 2024 and is projected to grow at a CAGR of 4.04% from 2025 to 2034. Other estimates place the global market size at USD 7.33 billion in 2024, expected to surpass USD 13.26 billion by 2031, or USD 8.00 billion in 2025, growing to USD 15.09 billion by 2034. North America dominated the dry eye syndrome market with a 47.03% share in 2025, and the U.S. market for dry eye syndrome is projected to reach USD 5.60 billion by 2032.

1. Launch and Commercialization of AXPAXLI (OTX-TKI) for wet Age-Related Macular Degeneration (AMD): Ocular Therapeutix presented detailed results from its SOL-1 Phase 3 superiority clinical trial for AXPAXLI in wet AMD in late February 2026. The company is optimistic about securing regulatory approval with a single pivotal trial and plans to submit a New Drug Application (NDA) based on the SOL-1 52-week data, potentially leveraging the 505(b)(2) pathway to shorten review times. AXPAXLI, an axitinib intravitreal implant, is anticipated to offer a commercial advantage due to its potential for a superiority label over existing treatments and a less frequent dosing regimen of every 6 to 12 months, which could significantly reduce the burden of care for patients.
2. Expansion of AXPAXLI (OTX-TKI) into Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME): Beyond wet AMD, Ocular Therapeutix is actively defining its clinical strategy for AXPAXLI in non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME). The company received positive feedback from the FDA regarding a potential registrational trial design for AXPAXLI in NPDR and is considering a streamlined development approach, potentially advancing with a single Phase 3 HELIOS-3 trial for diabetic retinal disease. This represents an opportunity to tap into a vast and largely untreated diabetic retinopathy market.
3. Continued Growth and Market Penetration of DEXTENZA: DEXTENZA, an FDA-approved dexamethasone ophthalmic insert for post-surgical ocular inflammation and pain and allergic conjunctivitis, currently serves as a revenue driver for the company. While 2025 saw a challenging reimbursement environment for DEXTENZA that led to a decrease in total net revenue, the company reported sustained growth in end-user unit sales. Moreover, DEXTENZA net product revenue demonstrated a 26.0% increase in Q2 2025 compared to the previous quarter, indicating a potential stabilization and recovery in sales.

Share Issuance

• In September 2025, Ocular Therapeutix completed an underwritten public offering of 37,909,018 shares at $12.53 per share, generating approximately $475 million in gross proceeds and $445 million in net proceeds.
• The company raised approximately $97 million in gross proceeds in June 2025 through its existing at-the-market (ATM) facility.
• Stockholders approved amendments in June 2025 to increase the number of shares available for issuance under its stock incentive and employee purchase plans by up to 10.75 million additional shares.

Inbound Investments

• Ocular Therapeutix received a $1 million milestone payment in the second quarter of 2023 from AffaMed Therapeutics Limited upon the NMPA's approval of AffaMed's Phase 3 Registrational Study.
• In the second quarter of 2022, the company received a $2 million clinical support payment from AffaMed Therapeutics Limited related to the dosing of the first subject in a Phase 2 clinical trial evaluating PAXTRAVA.
• A $1 million milestone payment was received in the fourth quarter of 2021 following FDA approval of a supplemental New Drug Application (sNDA) for DEXTENZA for allergic conjunctivitis.

Capital Expenditures

• Capital expenditures were reported as $12 million for the full year 2025.
• Capital expenditures were $1.29 million in 2024 and $6.09 million in 2023.
• Proceeds from the September 2025 equity offering are earmarked for infrastructure investments, including manufacturing capital expenditures, to support the development and potential commercialization of AXPAXLI™.